🎉 M&A multiples are live!
Check it out!

IKS Health Valuation Multiples

Discover revenue and EBITDA valuation multiples for IKS Health and similar public comparables like Monash IVF Group, Burjeel Holdings, and Ramsay Health.

IKS Health Overview

About IKS Health

Inventurus Knowledge Solutions Ltd is a technology enabled healthcare solutions provider, serving the U.S healthcare market. The group offer a comprehensive care enablement platform that supports healthcare enterprises across outpatient and inpatient care settings. It is operates in in Care Enablement, empowering healthcare organizations to deliver high-quality care efficiently and sustainably through an integrated platform that combines technology and deep human expertise. The Company operates in one reportable segment which is Healthcare. Its solutions are Revenue Cycle Management, Clinical Support, and Value-Based Care.


Founded

2006

HQ

India
Employees

7.5K+

Website

ikshealth.com

Financials

LTM Revenue $336M

LTM EBITDA $106M

EV

$3.2B

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 15K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

IKS Health Financials

As of November 2025, IKS Health reported last 12-month revenue of $336M and EBITDA of $106M.

In the same period, IKS Health generated $213M in LTM gross profit and $69.5M in net income.

See IKS Health valuation multiples based on analyst estimates

IKS Health P&L

In the most recent fiscal year, IKS Health reported revenue of $296M and EBITDA of $89.8M.

IKS Health expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See IKS Health valuation multiples based on analyst estimates
LTM NTM Last FY FY 2025 FY 2026 FY 2027
Revenue $336M XXX $296M XXX XXX XXX
Gross Profit $213M XXX $127M XXX XXX XXX
Gross Margin 64% XXX 43% XXX XXX XXX
EBITDA $106M XXX $89.8M XXX XXX XXX
EBITDA Margin 32% XXX 30% XXX XXX XXX
EBIT $93.3M XXX $73.3M XXX XXX XXX
EBIT Margin 28% XXX 25% XXX XXX XXX
Net Profit $69.5M XXX $54.1M XXX XXX XXX
Net Margin 21% XXX 18% XXX XXX XXX
Net Debt XXX XXX $63.9M XXX XXX XXX

Financial data powered by Morningstar, Inc.

IKS Health Stock Performance

IKS Health has current market cap of INR 279B (or $3.1B), and EV of INR 284B (or $3.2B).

Market Cap Evolution

IKS Health Stock Data

As of December 4, 2025, IKS Health's stock price is INR 1668 (or $19).

See IKS Health trading valuation data
EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$3.2B $3.1B XXX XXX XXX XXX $0.41

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Start Free Trial

IKS Health Valuation Multiples

IKS Health's trades at 11.6x EV/Revenue multiple, and 38.1x EV/EBITDA.

See valuation multiples for IKS Health and 15K+ public comps

IKS Health Financial Valuation Multiples

As of December 4, 2025, IKS Health has market cap of $3.1B and EV of $3.2B.

Equity research analysts estimate IKS Health's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

IKS Health has a P/E ratio of 44.6x.

LTM NTM Last FY FY 2025 FY 2026 FY 2027
Market cap (current) $3.1B XXX $3.1B XXX XXX XXX
EV (current) $3.2B XXX $3.2B XXX XXX XXX
EV/Revenue 9.4x XXX 11.6x XXX XXX XXX
EV/EBITDA 29.8x XXX 38.1x XXX XXX XXX
EV/EBIT 33.8x XXX 46.5x XXX XXX XXX
EV/Gross Profit 14.8x XXX n/a XXX XXX XXX
P/E 44.6x XXX 61.0x XXX XXX XXX
EV/FCF 48.8x XXX 113.2x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get IKS Health Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Start Free Trial

IKS Health Margins & Growth Rates

IKS Health's last 12 month revenue growth is 18%

IKS Health's revenue per employee in the last FY averaged $39K, while opex per employee averaged $7K for the same period.

IKS Health's rule of 40 is 48% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

IKS Health's rule of X is 77% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

See operational valuation multiples for IKS Health and other 15K+ public comps

IKS Health Operational Valuation Multiples

LTM NTM Last FY FY 2025 FY 2026 FY 2027
Revenue Growth 18% XXX 21% XXX XXX XXX
EBITDA Margin 32% XXX 30% XXX XXX XXX
EBITDA Growth 24% XXX 27% XXX XXX XXX
Rule of 40 48% XXX 48% XXX XXX XXX
Bessemer Rule of X XXX XXX 77% XXX XXX XXX
Revenue per Employee XXX XXX $39K XXX XXX XXX
Opex per Employee XXX XXX $7K XXX XXX XXX
S&M Expenses to Revenue XXX XXX 1% XXX XXX XXX
G&A Expenses to Revenue XXX XXX n/a XXX XXX XXX
R&D Expenses to Revenue XXX XXX n/a XXX XXX XXX
Opex to Revenue XXX XXX 18% XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

IKS Health Public Comps

See public comps and valuation multiples for Hospitals & Clinics comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Burjeel Holdings XXX XXX XXX XXX XXX XXX
PureHealth XXX XXX XXX XXX XXX XXX
Integral Diagnostics XXX XXX XXX XXX XXX XXX
Monash IVF Group XXX XXX XXX XXX XXX XXX
Ramsay Health XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

IKS Health M&A and Investment Activity

IKS Health acquired  XXX companies to date.

Last acquisition by IKS Health was  XXXXXXXX, XXXXX XXXXX XXXXXX . IKS Health acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by IKS Health

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 65K+ M&A deals.

Start Free Trial

About IKS Health

When was IKS Health founded? IKS Health was founded in 2006.
Where is IKS Health headquartered? IKS Health is headquartered in India.
How many employees does IKS Health have? As of today, IKS Health has 7.5K+ employees.
Is IKS Health publicy listed? Yes, IKS Health is a public company listed on NSE.
What is the stock symbol of IKS Health? IKS Health trades under IKS ticker.
When did IKS Health go public? IKS Health went public in 2024.
Who are competitors of IKS Health? Similar companies to IKS Health include e.g. Burjeel Holdings, PureHealth, Integral Diagnostics, Monash IVF Group.
What is the current market cap of IKS Health? IKS Health's current market cap is $3.1B
What is the current revenue of IKS Health? IKS Health's last 12 months revenue is $336M.
What is the current revenue growth of IKS Health? IKS Health revenue growth (NTM/LTM) is 18%.
What is the current EV/Revenue multiple of IKS Health? Current revenue multiple of IKS Health is 9.4x.
Is IKS Health profitable? Yes, IKS Health is EBITDA-positive (as of the last 12 months).
What is the current EBITDA of IKS Health? IKS Health's last 12 months EBITDA is $106M.
What is IKS Health's EBITDA margin? IKS Health's last 12 months EBITDA margin is 32%.
What is the current EV/EBITDA multiple of IKS Health? Current EBITDA multiple of IKS Health is 29.8x.
What is the current FCF of IKS Health? IKS Health's last 12 months FCF is $64.6M.
What is IKS Health's FCF margin? IKS Health's last 12 months FCF margin is 19%.
What is the current EV/FCF multiple of IKS Health? Current FCF multiple of IKS Health is 48.8x.

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.